MMSIMerit Medical Systems, Inc.

$87.22+4.4% 1Y

Is the price fair?

Fair

Neither cheap nor expensive: nothing decisive, though cheap against its own history.

1 good, 2 neutral
What the price assumes~+6% a year

Priced for ~6% a year FCF growth. Roughly in line with its three-year revenue growth of 10% a year.

Vs its own P/E rangecheaper than 94% of its own historyderived

Cheap vs its own history: P/E 35.9 vs a 53.7 median over 35 quarters (−33% vs median).

Vs sector (EV/EBIT)22.4×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 77% of the market
FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What MMSI's price assumes

Merit Medical Systems, Inc. trades at 35.9× earnings against 39.6× for the median Medical Instruments & Supplies name, cheaper than its own group.

35.9

Trailing P/E · Medical Instruments & Supplies median 39.6 · cheaper than the typical name in its group

Price / sales
2.68

Price / sales · today's price, trailing year to Jun 30, 2026

Free cash flow yield
4.8%

Free cash flow yield · Medical Instruments & Supplies median 3.4%

Growth the price implies
+6.2%

Growth the price implies · The price pays for +6.2% free cash flow growth a year for a decade; the business has delivered +61% a year over the last three.

Details›
Price / booktoday's price, trailing year to Jun 30, 2026
2.52
EV / EBITtoday's price, trailing year to Jun 30, 2026
22.4
EV / salestoday's price, trailing year to Jun 30, 2026
2.86
Healthcare median P/E509 names
26.2
Medical Instruments & Supplies median P/E33 names
39.6
Free cash flow, trailing twelve months
$203M
Market capitalisation
$4.23B
3-year revenue growth
+9.6%
3-year free cash flow growth
+61%
What the market has paid for these earnings: 35 quarters of its own multiple × $2.43 of trailing earnings per share
MethodPer share
Its own P/E history, lower quartile$109.21
Its own P/E history, median$130.57
Its own P/E history, upper quartile$188.40
52-week range$60.31 – $93.18
Today$87.22

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.